ESHAP explained

ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin's lymphoma. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R.^[1]

R-ESHAP consists of:

1. Rituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes
2. Etoposide, an epipodophyllotoxin topoisomerase inhibitor
3. Solu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes
4. High-dose Ara-C - cytarabine
5. Platinol - Cisplatin, a platinum-based antineoplastic agent, also an alkylating antineoplastic agent.

Dosing regimen

Drug	Dose	Mode	Days
	375 mg/m^2	IV infusion	Day 0
	40 mg/m^2	IV infusion over 1 hr	Days 1-4
	500 mg	IV bolus over 15 min	Days 1-5
	2000 mg/m^2	IV infusion over 2 hrs	Day 5
	25 mg/m^2	IV continuous infusion over 24 hrs	Days 1-4

Notes and References

1. http://jco.ascopubs.org/content/12/6/1169.abstract ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.